Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, accusing Lilly of misleading advertising about their weight-loss drug efficacy. Novo argues that Lilly's ads compare Lilly's Zepbound to an older, lower-dose version of Novo's Wegovy, ignoring Novo's newer, more effective 7.2 mg Wegovy dose. The dispute highlights fierce competition in the GLP-1 weight-loss drug market, with Novo promoting its new Wegovy pill and Lilly defending its advertising as truthful. Market shares are shifting as both companies compete aggressively in this growing sector.
Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...
Novo Nordisk CEO Mike Doustdar highlighted the early stage of GLP-1 drug adoption for obesity treatment, noting that over 100 million Americans suffer from obesity but only about 10-15% have used these medications. He emphasized the potential for the...
Novo Nordisk remains a Buy due to its strong long-term fundamentals and leadership in obesity treatment, particularly with its Wegovy pill. Although the company faces short-term issues like declining gross margins, high capital expenditures, and a fa...
Novo Nordisk has received a "Sell" rating due to growing competition from Eli Lilly and internal challenges like expiring patents and manufacturing issues. An analyst set a cautious price target of $47, reflecting concerns over flat to negative growt...
